Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly’s Lartruvo Withdrawal Stirs Questions About Payment For Accelerated Approval Drugs

Executive Summary

News that the soft tissue sarcoma drug will come off the market after its confirmatory trial failed to verify clinical benefit spurs Memorial Sloan-Kettering’s Peter Bach to ask whether Lilly will refund money to payers.


Related Content

BIO 2019 Notebook: M&A Soars, Lartruvo Lookback, BIO Vs. ASCO
BIO 2019 Notebook: Lartruvo Lookback, M&A Soars, BIO Vs. ASCO
Lartruvo Could Be A Failure Of The Drug, The Design Or The Disease
Keeping Track: A Glut Of Big Approvals While Lartruvo Makes Its Market Exit
No New Patients For Lartruvo In EU After Trial Failure
Lartruvo Phase III Fail Rocks Lilly Oncology Plans
Valuing Drugs In The US: How We're Doing And What's Ahead
NEJM Takes Aim At Expensive Accelerated Approval Drugs Amid Congressional Drug Pricing Debate
Lilly's Sarcoma Drug Likely To Be Used Widely Despite EU Conditional OK
Lilly's Lartruvo Scores Broad FDA Approval In Orphan Sarcomas


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts